Key facts
- Celaid Therapeutics’s last known valuation is $20.2M (Oct 2025).
- It has raised $14.5M; the latest was Later Stage VC ($7.1M) in Oct 2025.
- Notable investors include Japan External Trade Organization, Mirai Cross, The University of Tokyo Edge Capital, UTokyo Innovation Platform Company, Osaka University Venture Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Celaid Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Celaid Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Celaid Therapeutics
Developer of a regenerative medicine platform designed to develop cell therapy products. The company's platform offers medicines created using human hematopoietic stem cell expansion technology and offers research support for media reagents, enabling medical professionals to get hematopoietic stem cell transplantation and cell therapy products combined with gene-editing technology.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2020
- Employees
- 18
- Website
- celaidtx.com/
- Ownership
- Privately Held (backing)
Celaid Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celaid Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celaid Therapeutics in its N-PORT filings yet. We sweep new filings monthly.